Naslov
Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023

Autori
Kissling, Esther ; Maurel, Marine ; Emborg, Hanne- Dorthe ; Whitaker, Heather ; McMenamin, Jim ; Howard, Jennifer ; Trebbien, Ramona ; Watson, Conall ; Findlay, Beth ; Pozo, Francisco ; Bolt Botnen, Amanda ; Harvey, Ciaran ; Rose, Angela ; European IVE group

Izvornik
Eurosurveillance (1560-7917) 28 (2023), 21; 2300116, 16

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
influenza ; vaccine effectiveness ; season 2022/2023 ; primary care ; hospital
(influenza, vaccine effectiveness, season 2022/2023, primary care, hospital)

Sažetak
Background Between October 2022 and January 2023, influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe with different influenza (sub)types dominating in different areas. Aim To provide interim 2022/23 influenza vaccine effectiveness (VE) estimates from six European studies, covering 16 countries in primary care, emergency care and hospital inpatient settings. Methods All studies used the test- negative design, but with differences in other study characteristics, such as data sources, patient selection, case definitions and included age groups. Overall and influenza (sub)type- specific VE was estimated for each study using logistic regression adjusted for potential confounders. Results There were 20, 477 influenza cases recruited across the six studies, of which 16, 589 (81%) were influenza A. Among all ages and settings, VE against influenza A ranged from 27 to 44%. Against A(H1N1)pdm09 (all ages and settings), VE point estimates ranged from 28% to 46%, higher among children (< 18 years) at 49–77%. Against A(H3N2), overall VE ranged from 2% to 44%, also higher among children (62–70%). Against influenza B/Victoria, overall and age-specific VE were ≥ 50% (87–95% among children < 18 years). Conclusions Interim results from six European studies during the 2022/23 influenza season indicate a ≥ 27% and ≥ 50% reduction in disease occurrence among all- age influenza vaccine recipients for influenza A and B, respectively, with higher reductions among children. Genetic virus characterisation results and end-of-season VE estimates will contribute to greater understanding of differences in influenza (sub)type-specific results across studies.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita

Napomena
European IVE group members
CROATIA EU-H and EU-PC studies:
Vesna Višekruna Vučina (Croatian Institute of Public Health, Zagreb), Maja Ilić
(Croatian Institute of Public Health, Zagreb), Goranka Petrović (Croatian
Institute of Public Health, Zagreb), Ivan Mlinarić (Croatian Institute of Public
Health, Zagreb), Sanja Kurečić Filipović (Croatian Institute of Public Health,
Zagreb), Bernard Kaić (Croatian Institute of Public Health, Zagreb), Iva Pem
Novosel (Croatian Institute of Public Health, Zagreb), Ivana Ferenčak (Croatian
Institute of Public Health, Zagreb), Irena Tabain (Croatian Institute of Public
Health, Zagreb), Katica Čusek Adamić (Institute of Public Health, Varaždin
County), Mirjana Lana Kosanović Ličina (“Dr. Andrija Štampar” Teaching Institute
of Public Health, Zagreb), Danijela Lakošeljac (Teaching Institute of Public
Health, Primorje-Gorski kotar County), Ivana Mihin Huskić (Teaching Institute of
Public Health, Osijek-Baranja County), Diana Nonković (Teaching Institute of
Public Health, Split-Dalmatia County).

POVEZANOST RADA